chartexchange

Yarrow Bioscience Reports Third Quarter 2026 Financial Results and Provides Business Update

Business Wire | Nov 12, 2026 7:00 AM EST

NEW HAVEN, Conn.--(BUSINESS WIRE)--Yarrow Bioscience, Inc. (“Yarrow” or the “Company”) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced financial results for the third quarter ended September 30, 2026, and provided a business update. “We made significant progress in the third quarter, including dosing our first patient in the Phase 2a portion of the DIRECTION-GD trial and strengthening our bala

Read original article